Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 3/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.41 |
| ▸ | ADRA2A | P08913 | 3/20 | 0.41 |
| ▸ | DRD1 | P21728 | 3/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.41 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.41 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.41 |
| ▸ | HTR2A | P28223 | 2/20 | 0.41 |
| ▸ | HRH1 | P35367 | 2/20 | 0.41 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5113337 | 0.78 | CYP2D6 (0.42) | CYP2D6CYP2C19ALDH1A1CHRM2ADRA2A | |
| SCHEMBL1448809 | 0.77 | CYP2D6 (0.41) | CYP2D6CYP2C19ALDH1A1CHRM2ADRA2A | |
| SCHEMBL29933293 | 0.75 | CYP2D6 (0.48) | CYP2D6CYP2C19ALDH1A1CHRM2ADRA2A | |
| SCHEMBL12574809 | 0.75 | CYP2D6 (0.48) | CYP2D6CYP2C19ALDH1A1CHRM2ADRA2A | |
| SCHEMBL29635663 | 0.75 | — | — | |
| SCHEMBL231127 | 0.75 | CYP2D6 (0.57) | CYP2D6CYP2C19ALDH1A1CHRM2ADRA2A | |
| SCHEMBL6644008 | 0.75 | KMT2A (0.32) | TSHRATMKMT2A | |
| SCHEMBL364 | 0.75 | — | — | |
| SCHEMBL1185718 | 0.75 | CYP2D6 (0.44) | CYP2D6CYP2C19ALDH1A1CHRM2ADRA2A | |
| SCHEMBL1186136 | 0.75 | CYP2D6 (0.41) | CYP2D6CYP2C19ALDH1A1CHRM2ADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 213 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7402595-B2 | Enzyme inhibitors with isoquinolinone structures | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-07-22 | — | — | US | claimed |
| US-20050148624-A1 | Jnk inhibitor | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-07-07 | — | — | US | claimed |
| EP-1484320-A1 | JNK INHIBITOR | Takeda Chemical Industries, Ltd. (JP) | 2004-12-08 | — | — | EP | claimed |
| US-20030232864-A1 | Novel Compounds and compositions as protease inhibitors | AXYS PHARMACEUTICALS, INC. (US) | 2003-12-18 | — | — | US | claimed |
| JP-2002539201-A | — | — | 2002-11-19 | — | — | JP | claimed |
| US-6352985-B1 | CARDIOVASCULAR DISORDERS OR GASTROINTESTINAL DISORDERS, DIABETES (TYPE II DIABETES), DIABETIC COMPLICATIONS METHOD FOR LOWERING THE BLOOD SUGAR LEVEL OF A PATIENT, | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-03-05 | — | — | US | claimed |
| EP-1161422-A1 | AMINE DERIVATIVES AS PROTEASE INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2001-12-12 | — | — | EP | claimed |
| WO-2000055144-A1 | AMINE DERIVATIVES AS PROTEASE INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2000-09-21 | — | — | WO | claimed |
| EP-0882718-A1 | BENZIMIDAZOLE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1998-12-09 | — | — | EP | claimed |
| US-5707989-A | ANTITUMOR AGENTS, INHIBITING SIGNAL TRANSDUCTION MEDIATED BY TYROSINE KINASES | DR. KARL THOMAE GMBH (DE) | 1998-01-13 | — | — | US | claimed |
| WO-2024071216-A1 | PYRAZOLE COMPOUND AND PEST CONTROL AGENT CONTAINING SAME AS ACTIVE INGREDIENT | 三井化学クロップ＆ライフソリューション株式会社 | 2024-04-04 | — | — | WO | disclosed |
| WO-2023171783-A1 | PYRAZOLE COMPOUND, AND NOXIOUS ORGANISM CONTROL AGENT CONTAINING SAME AS ACTIVE INGREDIENT | 三井化学アグロ株式会社 | 2023-09-14 | — | — | WO | disclosed |
| EP-3237410-B1 | AZOLINE COMPOUNDS SUBSTITUTED BY A CONDENSED RING SYSTEM | BASF SE (DE) | 2020-12-16 | — | — | EP | disclosed |
| US-10273231-B2 | Azoline compounds substituted by a condensed ring system | BASF SE (DE) | 2019-04-30 | — | — | US | disclosed |
| US-20190040050-A1 | AZOLINE COMPOUNDS SUBSTITUTED BY A CONDENSED RING SYSTEM | BASF SE (DE) | 2019-02-07 | — | — | US | disclosed |
| US-5142048-A | Enzyme inhibitor; carbamoyl group-containing acids | FUJISAWA PHARMACEUTICAL COMPANY, LTD. (JP) | 1992-08-25 | — | — | US | disclosed |
| EP-0465368-A1 | Sulfur derivatives of imidazole, process for their preparation, intermediates, their use as medicaments, and pharmaceutical compositions containing them | ROUSSEL UCLAF (FR) | 1992-01-08 | — | — | EP | disclosed |
| EP-0457195-A2 | Peptides having endothelin antagonist activity, a process for preparation thereof and pharmaceutical compositions comprising the same | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1991-11-21 | — | — | EP | disclosed |
| US-4921855-A | New Histidyl amino acid derivatives, and pharmaceutical composition comprising the same | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1990-05-01 | — | — | US | disclosed |
| EP-0300189-A2 | New amino acid derivatives, processes for the preparation thereof and pharmaceutical composition comprising the same | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1989-01-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190040050-A1 | AZOLINE COMPOUNDS SUBSTITUTED BY A CONDENSED RING SYSTEM | CUL5, CUL1, CUL3 | CYP2D6 1262/4885CYP2C19 576/4885ALDH1A1 1791/4885 |
| US-20050148624-A1 | Jnk inhibitor | MAPK3, MAPKAPK3, MAPK1 | CYP2D6 2177/4885CYP2C19 2406/4885ALDH1A1 4549/4885 |
| US-20030232864-A1 | Novel Compounds and compositions as protease inhibitors | SERPINB1, CTRL, CTSZ | CYP2D6 2574/4885CYP2C19 1822/4885ALDH1A1 3027/4885 |
| US-10273231-B2 | Azoline compounds substituted by a condensed ring system | CUL5, CUL1, CUL3 | CYP2D6 1262/4885CYP2C19 576/4885ALDH1A1 1791/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.